Back
Science

Novel Gut Microbiome Therapy Shows Broad Symptom Improvements in Children with Autism in Early Study

Generated on: Last updated: 1 sources
View source

Novel Fecal Microbiota Transplant Method Investigated for Autism Spectrum Disorder

A recent study published in Frontiers in Pediatrics investigated a novel fecal microbiota transplant (FMT) method utilizing hydrogen nanobubble water as a potential treatment for autism spectrum disorder (ASD) in children.

The study aimed to evaluate the efficacy and safety of this approach without the use of antibiotics or bowel cleansing.

ASD Background and Treatment Challenges

ASD is a neurodevelopmental condition characterized by difficulties in social communication and interaction, restricted interests, repetitive behaviors, and altered sensory processing. The Centers for Disease Control and Prevention (CDC) reported a significant rise in prevalence: 1 in 36 eight-year-olds in the U.S. were diagnosed in 2020, compared to 1 in 68 a decade prior.

Current behavioral therapies for ASD have limitations in consistency and scalability. No existing treatment provides consistent, stable improvements for all patients.

Research suggests the gut microbiota may contribute to ASD pathogenesis through the gut-brain axis. Observed differences in gut bacterial composition are common in children with ASD. Prior FMT investigations have reported short-term reductions in ASD symptoms but often involved antibiotic pretreatment and polyethylene glycol (PEG)-based bowel cleansing.

Study Design and Methodology

This prospective single-arm study involved 30 participants with ASD, with an approximate 3:1 male-to-female ratio. The novel fecal microbiota solution, termed SHIN-1, was prepared under GMP guidelines, diluted, and stored refrigerated.

It was administered rectally via catheter or enema in various dose variants (3–13 g) mixed with saline.

Efficacy was assessed using multiple tools:

  • Social Responsiveness Scale (SRS-2): Measured core ASD symptoms in social communication and interaction (SCI) and restricted/repetitive behavior (RRB) domains.
  • Short Sensory Profile (SSP): Evaluated sensory processing.
  • Gastrointestinal Symptom Rating Scale (GSRS) and Bristol Stool Form Scale (BSFS): Assessed gastrointestinal (GI) symptoms.
  • PHQ-4: Screened for depression and anxiety.

Key Findings

The SHIN-1 protocol did not require antibiotics or intestinal cleansing.

Microbiome analysis 24 weeks post-treatment indicated a shift towards bacterial taxa commonly found in neurotypical children, including increases in Bacteroides, Prevotella, Akkermansia, and Clostridium Cluster XVIII. However, a consistent microbial signature was not defined across all participants.

ASD Severity (SRS-2)

  • Overall ASD severity declined by approximately 29% over 30 weeks across all subjects.
  • Roughly two-thirds of participants moved from severe or moderate to milder categories, with 6 participants entering the normal range.
  • Subjects without co-occurring GI disorders experienced a 45% SRS-2 reduction into the normal range, compared to 24% in those with GI involvement.

Social Communication and Interaction (SCI)

  • SCI Scores decreased by 28% across all four subscales (social awareness, social cognition, social communication, social motivation).

Restricted/Repetitive Behavior (RRB)

  • RRB severity declined by 33%.
  • SRS-2 findings were corroborated by Gazefinder gaze-tracking measures of social attention.

Sensory Processing Disorder (SSP)

  • Overall severity fell by 30% among 26 subjects, with comparable reductions across hyposensitivity, hypersensitivity, and hyporesponsiveness/sensation seeking subtypes.

Anxiety and Depressive Symptoms (PHQ-4)

  • Symptoms decreased by 50% in 87% of participants.

Safety

  • No adverse events were observed in the cohort, although the small sample size limits definitive safety conclusions.

Conclusions and Limitations

The trial suggests that this gut microbiota-targeted intervention may lead to broad improvements across core and peripheral ASD symptom domains, including behavioral severity, sensory dysregulation, GI dysfunction, and psychiatric comorbidities, without antibiotics or invasive preparation.

However, the findings should be interpreted cautiously due to several limitations:

  • Absence of a randomized control group.
  • Small sample size.
  • Single-donor design.
  • Geographically limited cohort.
  • The study received partial internal funding and included an author affiliated with the developing company.

The researchers recommend further investigation through larger, double-blind, placebo-controlled trials to validate these early outcomes.